People: GenVec Inc (GNVC.OQ)

GNVC.OQ on NASDAQ Stock Exchange Capital Market

2.47USD
31 Jul 2015
Change (% chg)

$0.18 (+7.86%)
Prev Close
$2.29
Open
$2.32
Day's High
$2.48
Day's Low
$2.32
Volume
3,028
Avg. Vol
7,900
52-wk High
$4.67
52-wk Low
$1.61

Search Stocks

Summary

Name Age Since Current Position

Wayne Hockmeyer

70 2013 Chairman of the Board

Douglas Swirsky

45 2014 President, Chief Executive Officer, Corporate Secretary, Director

James Lambert

50 2014 Chief Financial Officer, Chief Accounting Officer, Senior Director, Controller, Treasurer

Bryan Butman

62 2012 Senior Vice President - Development

Douglas Brough

60 2013 Chief Scientific Officer

Stefan Loren

51 2013 Director

Quinterol Mallette

41 2014 Director

Michael Richman

53 2015 Director

William Kelley

76 2002 Independent Director

Marc Schneebaum

60 2007 Independent Director

Rena Cohen

2013 IR Contact Officer

Biographies

Name Description

Wayne Hockmeyer

Dr. Wayne T. Hockmeyer, Ph.D., is Chairman of the Board of Genvec, Inc. Dr. Hockmeyer founded MedImmune, Inc. (MedImmune) in April 1988 as President and Chief Executive Officer and was elected a director of MedImmune in May 1988. Dr. Hockmeyer became Chairman of the board of directors of MedImmune in May 1993 and left his position as Chief Executive Officer in October 2000. Dr. Hockmeyer is currently retired, having resigned from his positions as a member of the MedImmune board of directors and as President of MedImmune Ventures, Inc. following the acquisition of MedImmune by AstraZeneca Biopharmaceuticals, Inc. in June 2007. Dr. Hockmeyer earned his bachelor’s degree from Purdue University and his Ph.D. from the University of Florida in 1972. Currently, he is a director of Baxter International Inc., and the Indian River Medical Center. Within the past five years, Dr. Hockmeyer served on the board of directors of Idenix Pharmaceuticals, Inc.

Douglas Swirsky

Mr. Douglas J. Swirsky is President, Chief Executive Officer, Corporate Secretary, Director of GenVec, Inc. He joined GenVec in 2006 as Chief Financial Officer, Treasurer, and Corporate Secretary; and continues to serve as Corporate Secretary. Prior to joining GenVec, Mr. Swirsky was a Managing Director and the Head of Life Sciences Investment Banking at Stifel Nicolaus from 2005 to 2006 and held investment banking positions at Legg Mason from 2002 until Stifel Financial’s acquisition of the Legg Mason Capital Markets business in 2005. Mr. Swirsky, a Certified Public Accountant and a holder of a Chartered Financial Analyst® designation, has also previously held investment banking positions at UBS, PaineWebber, and Morgan Stanley. His experience also includes positions in public accounting and consulting. Mr. Swirsky received his B.S. in Business Administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Swirsky is a member of the Board of Directors of Fibrocell Science, Inc. Within the past five years, Mr. Swirsky has also served on the board of PolyMedix, Inc.

James Lambert

Mr. James V. Lambert is Senior Director, Accounting and Finance, Corporate Controller and Treasurer. Prior to joining GenVec, from 1999 to 2006, Mr. Lambert was the Controller at Sigma Tau Pharmaceuticals, the North American distributor of pharmaceutical drugs, dietary supplements, and fine chemicals for an Italian company. Previously, he served as Controller for Stone Street Capital, Inc., Accounting Manager for OncorMed, Inc., and in various positions with increasing levels of responsibility at Blue Cross Blue Shield of the National Capital Area. Mr. Lambert began his career as an analyst for E-Systems, Melpar Division. Mr. Lambert, a Certified Public Accountant, received a B.A. in Economics and a B.S. in Accounting from the University of Maryland.

Bryan Butman

Dr. Bryan T. Butman, Ph.D., is Senior Vice President of Development of GenVec, Inc. He joined GenVec in 1999 and previously served as GenVec’s Vice President of Vector Operations (2005 to 2006), Vice President of Quality (2002 to 2005) and Director of Quality and Analytical Science (1999 to 2002). Prior to joining GenVec, Dr. Butman was Executive Director of Diagnostic Product Research and Development with INTRACEL Corporation, a biotechnology company. Dr. Butman has over 30 years of biotechnology product development experience including clinical gene therapy, human monoclonal antibody and clinical diagnostic products. Throughout his biotechnology career, Dr. Butman has developed successful products in the areas of oncology, cardiovascular disease, infectious disease, food safety and hematology. He has held senior positions within Warner Lambert, AKZO-Nobel, Organon Teknika, PerImmune and INTRACEL. Dr. Butman holds a Ph.D. in Cell Biology from Wayne State University.

Douglas Brough

Dr. Douglas E. Brough, Ph.D., is Chief Scientific Officer since September 2013. Dr. Brough previously held several positions at GenVec including Senior Vice President, Research, Vice President, Head of Research, Executive Director of Vector Sciences, Senior Director of Vector Sciences, Director of Vector Sciences, Director of Molecular Virology, Head Molecular Virology and Research Scientist. Prior to joining GenVec, Dr. Brough was a Research Fellow in the Department of Molecular Biology at the Lewis Thomas Laboratory, Princeton University. Dr. Brough received his B.S. in Biology from Purdue University, a M.S. in Microbiology and Biochemistry from Idaho State University and his Ph.D. in Microbiology and Molecular Genetics from Rutgers, the State University of New Jersey and the Robert Wood Johnson Medical School. Dr. Brough performed post-doctoral research in molecular biology at Princeton University.

Stefan Loren

Dr. Stefan D. Loren, Ph.D., has been appointed as Director of GenVec, Inc., effective September 19, 2013. Dr. Loren is a member of the Audit Committee and the Nominating and Corporate Governance Committee. Dr. Loren was initially recommended as a director candidate by one of our stockholders. Since March 2014, Dr. Loren has been engaged in founding Loren Capital Strategy, an investment fund. Dr. Loren was a Managing Director of Westwicke Partners, a healthcare-focused consulting firm, from 2008 through February 2014. From 2007 to 2008, Dr. Loren was an Analyst with Perceptive Advisors, a healthcare-focused investment fund, and, prior to that, served as an analyst and portfolio manager for MTB Investment Advisors from 2005 to 2007. Prior to 2005, Dr. Loren was a Managing Director in the healthcare equity research group at Legg Mason, and before joining Legg Mason, a Research Chemist at the advanced technologies division of Abbott Laboratories and a Research Fellow at the Scripps Research Institute. Dr. Loren received his B.A. from the University of California, San Diego, and his Ph.D. from University of California, Berkeley. Currently, he is a director of Marina Biotech, Inc. Within the past five years, Dr. Loren has served on the boards of directors of Orchid Cellmark Inc. and Polymedix, Inc.

Quinterol Mallette

Mr. Quinterol J. Mallette, M.D., is Director of GenVec, Inc. Dr. Mallette is currently a Senior Analyst at SWK Holdings, Inc., a publicly-traded healthcare-focused specialty finance firm, a position he has held since 2013. From 2011 to 2013, Dr. Mallette was the Founder and President of Mallette Research Associates, a provider of in-depth, real-time equity research to brokerage houses. From 2009 to 2011, Dr. Mallette was the Founder and President of the Invictus Trading Group, Inc., a proprietary trading group with expertise in healthcare. Dr. Mallette began his career in 2001 at Lehman Brothers as an Equity Research Analyst in the Biotechnology space. Dr. Mallette left Lehman to fill the role of Senior Analyst for a healthcare-dedicated fund, before starting his own fund. Dr. Mallette holds B.S. degrees in Biomedical Engineering and Psychology from Duke University. He also received an MBA from the Fuqua School of Business at Duke University and a medical degree from the Duke University School of Medicine.

Michael Richman

Mr. Michael S. Richman is Director of GenVec, Inc. Mr. Richman has served as the president and chief executive officer of Amplimmune, a member of the AstraZeneca group since 2013. Prior to Amplimmune's acquisition by AstraZeneca, he was president and chief executive officer of the company when it was a privately held biologics company focused on cancer and autoimmune diseases. Mr. Richman served as president of Amplimmune from 2007 through 2008. From 2002 through 2007, he was the executive vice president and chief operating officer of MacroGenics, a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disorders and infectious diseases. Mr. Richman has over 30 years of experience working in research, intellectual property and business development capacities in companies such as Chiron Corporation (now Novartis) and MedImmune, Inc. (prior to AstraZeneca's acquisition), where he was senior vice president corporate development. While at MedImmune, Mr. Richman was responsible for all business development, licensing, intellectual property, legal affairs, project management and strategic planning functions, and drove many significant transactions during that period. Mr. Richman is also member of the board of directors of Opexa Therapeutics, Inc., a public company, Madison Vaccines, Inc., a private company, and Pieris Pharmaceuticals, Inc., a public company. He also served as a director of Cougar Biotechnology until its acquisition by Johnson & Johnson. Mr. Richman obtained his B.S. in genetics/molecular biology at the University of California at Davis and his M.S.B.A. in international business at San Francisco State University.

William Kelley

Dr. William N. Kelley, M.D., is Independent Director of Genvec, Inc. Dr. Kelley is Chairman of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Dr. Kelley and his colleagues at the University of Michigan were the first to show proof of concept data for in vivo gene therapy as it is recognized today. From 1989 to 2000, Dr. Kelley served as Executive Vice President of the University of Pennsylvania with responsibilities as Chief Executive Officer for the Medical Center, Dean of the School of Medicine, and the Robert G. Dunlop Professor of Medicine and Biochemistry and Biophysics. He is currently Professor of Medicine at the School of Medicine of the University of Pennsylvania. In the national leadership arena, Dr. Kelley has served as President of the American Society for Clinical Investigation, President of the American College of Rheumatology, Chair of the American Board of Internal Medicine, and Chair of the Residency Review Committee for Internal Medicine. Within the past five years, Dr. Kelley served on the board of directors of Merck & Co. Inc., Beckman Coulter, Inc., Advanced Biosurfaces, Inc., Polymedix, Inc., and he now also serves on the board of directors of Transenterix, Inc.

Marc Schneebaum

Mr. Marc R. Schneebaum is Independent Director of Genvec, Inc. Mr. Schneebaum has served as the Chief Financial Officer and Senior Vice President of Synta Pharmaceuticals Corp. since December 2014. Mr. Schneebaum has also served as an industry consultant. Mr. Schneebaum served as President, Chief Executive Officer and a director of Predictive BioSciences, Inc., a commercial stage cancer diagnostics company, from 2011 to 2013. From 1997 to 2010, Mr. Schneebaum served as President, Chief Executive Officer, and a director of Sensors for Medicine and Science, Inc., an emerging medical technology company. From 1991 to 1997, he served as Senior Vice President, Finance, Business Development and Administration, and Chief Financial Officer of Genetic Therapy, Inc., a biotechnology company (acquired by Sandoz/Novartis). From 1987 to 1991, Mr. Schneebaum was a Vice President at Alex Brown & Sons Incorporated, a leading investment banking firm (now part of Deutsche Bank), where he participated in a variety of finance and strategic assignments. Mr. Schneebaum began his career in the accounting and auditing group at KPMG LLP, advancing to Senior Manager in the management consulting group. Mr. Schneebaum, a Certified Public Accountant (inactive), received his degree in Business Administration from the University of Maryland.

Rena Cohen

Basic Compensation

Search Stocks